By

Admin
Results from a new study at Hutchinson Cancer Research Cancer in Seattle suggests that chimeric antigen receptor (CAR) T-cell therapy can be further improved for multiple myeloma. The approach relies on a class of drugs known as gamma-secretase inhibitors (GSIs), several of which have been studied to treat Alzheimer disease but were never approved for...
Continue Reading
The Prime Minister has acknowledged Blair Vining’s “tireless advocacy” as the new independent Cancer Control Agency was formally opened on Tuesday. During Vining’s final months, as he was dying from cancer, the Southlander pushed for the Government to set up an independent cancer agency to improve cancer care for New Zealanders. In September, a matter of weeks before Vining died,...
Continue Reading
Starting Saturday, December 7, HemOnc Today will be onsite in Orlando at the ASH Annual Meeting and Exposition, bringing the latest in important, novel hematology research to our daily feed, with a special focus on multiple myeloma. HemOnc Today spoke with Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center,...
Continue Reading
The objective of the study was to assess racial disparities in the treatment and outcomes among white, African American, and Hispanic patients with multiple myeloma (MM). Patients with an MM diagnosis from the Surveillance Epidemiology and End Results (SEER)–Medicare (2007-2013) database were included. Continuous Medicare enrollment for 6 months before (baseline) and after MM diagnosis...
Continue Reading
Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function. Wednesday 11 December, 5.00pm at BNZ Partners Centre, Level 10 Ricoh House, 1 Victoria Street, Wellington. Guest speaker: Dr Henry Chan, Consultant Haematologist, North Shore Hospital “Latest myeloma update from recent international conferences” RSVP by Friday 6 December...
Continue Reading
There are issues involving Pharmac and how they fund medicines – Pharmac does not adopt international guidelines; it does not set a timeframe by which it will be decided if a medicine is efficacious and another timeframe when it will endeavour to fund a medicine if it is deemed to be efficacious; it needs to...
Continue Reading
The U.S. Food and Drug Administration (FDA) approved the quadruplet regimen consisting of daratumumab, bortezomib, thalidomide, and dexamethasone to treat adult patients with newly diagnosed multiple myeloma who are eligible for autologous hematopoietic cell transplantation. This approval is based on data from the open-label, randomized phase III CASSIOPEIA trial, which compared induction and consolidation treatment...
Continue Reading
Myeloma New Zealand submitted an online response to the plan on behalf of myeloma patients, pointing in particular to the need for full inclusion of blood cancers in the plan’s focus, and prioritisation of the need for equitable access to modern medications. Read the response here
Continue Reading
Newly diagnosed patients with myeloma who are about to start treatment may benefit from a fixed course of prophylactic antibiotics to prevent Pneumocystis pneumonia, new research suggests. The double-blind phase III randomised TEAMM trial of almost 1,000 newly diagnosed patients showed that a 12-week course of levofloxacin (500mg daily) during myeloma treatment reduced the incidence...
Continue Reading
An update of the Medicines Waiting List report has just been released. The Medicines Waiting List shows how long patients have been waiting for medicines that have been positively recommended by PHARMAC’s clinical expert committee PTAC but are not yet funded by PHARMAC. This report is the fifth of it’s type and also compares the current waiting...
Continue Reading
1 2 3 20

Floor 7, 90 The Terrace
Wellington Central
New Zealand